Active Lungs & Breathing NIHR-supported project Infection & Immunity
A Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (CTD).
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Fasihul Khan (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (C...
A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group treatment study to evaluate the efficacy and safety of belimumab administered subcutaneously in adult participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis (dcSSc-ILD)
A Phase 2 Placebo-controlled Double Blinded Study to Assess the Efficacy and Safety of Belimumab in Subjects with Immunoglobulin A Nephropathy (IgAN)
An open label study to investigate the long-term safety and efficacy of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)
A randomized, double blind controlled trial comparing Rituximab against intravenous Cyclophosphamide in Connective Tissue Disease (CTD) associated Interstitial Lung Disease (ILD) RECITAL
Original classification
RespiratoryPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know